about
LRP-1: a checkpoint for the extracellular matrix proteolysisPlasminogen activator inhibitor-1 deposition in the extracellular matrix of cultured human mesangial cellsCloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysisExtracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factorThe proteinase activated receptor-2 (PAR-2) mediates mitogenic responses in human vascular endothelial cellsComplexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptorReverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissueIntegrating with integrinsDirect binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activityFunctional structure of the somatomedin B domain of vitronectinCloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitorThe receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexesProteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned mediumVascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesisExpression of plasminogen activators in preimplantation rat embryos developed in vivo and in vitroInvasion and metastasis in pancreatic cancerC766T low-density lipoprotein receptor-related protein 1 (LRP1) gene polymorphism and susceptibility to breast cancerHuman breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activityPlasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision MedicineAnticancer Efficacy of Polyphenols and Their CombinationsModulation of CD44 Activity by A6-PeptideUltrastructure of the vitreoretinal interface following plasmin assisted vitrectomyA plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiationBlood peptidome-degradome profile of breast cancerAccessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitorNeutralisation of uPA with a monoclonal antibody reduces plasmin formation and delays skin wound healing in tPA-deficient miceExtracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancerSoluble fibrin preparations inhibit the reaction of plasmin with alpha 2-macroglobulin. Comparison with alpha 2-antiplasmin and leupeptin.Differential modulation of plasminogen activator gene expression by oncogene-encoded protein tyrosine kinasesNeuroserpin is expressed in the pituitary and adrenal glands and induces the extension of neurite-like processes in AtT-20 cells.Detection of vitronectin mRNA in tissues and cells of the mouseThe plasminogen activation system enhances brain and heart invasion in murine relapsing fever borreliosis.Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis kneesFacultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor 2The plasmin cascade and matrix metalloproteinases in non-small cell lung cancerType 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoterBRMS1 suppresses glioma progression by regulating invasion, migration and adhesion of glioma cells.Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor.Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.
P2860
Q21285122-1D316534-E792-4BE1-940E-E3E885A5010EQ24297830-55E42147-E8BA-453D-B7A6-3239961544CBQ24299135-D72428CA-727F-470D-B594-6DEC77980345Q24555664-6252927F-9FF9-476E-BF6D-4D601673BA3AQ24562218-1FF4EA61-9F61-4833-9F10-7F2CD254744FQ24564351-26604436-020D-4348-AC7C-A5EBD8FB6716Q24614528-DC399E86-2067-42B9-A60D-D04FC11D63CBQ24620638-35CE0BA3-FF8E-4FA4-A005-EE37D3ACACBDQ24633333-C4DA6EAC-6C1D-43FD-96C1-81E9D0169C44Q24648799-E059B6C6-EB4C-4C7C-9CA9-65C728182CD9Q24655336-7CE92BE8-FE53-422C-BC61-D855EFF07FFEQ24678932-539A8ECC-5C88-49B9-B6BE-45E2F84D5C14Q24679838-FF2A0408-BFA2-445A-A22B-AF7BAF42ED25Q24684263-66DBF68D-81AF-45BD-A0E4-78483CC1D478Q24792833-C75BCB94-8F80-4FD4-9CCB-3EBBB948F43DQ24800065-E2816372-B6C1-4F7A-BA1B-0223851BCBFAQ24803584-65319510-6F67-4C30-BA10-AF862AEE48B2Q24803810-C7116E99-CB3D-4B76-A5E5-FD4234980E21Q28067626-92B371EA-4EBD-45E0-A47D-6FE4E910B7EDQ28076137-A74E9642-F680-49BA-86EC-B89909D71F96Q28085166-E36DCA6C-8287-46E9-B3AB-5C4E9A29F1F4Q28345338-33A1A8A0-B797-474B-AC57-F69E8B57266FQ28357136-7D091E2E-7808-4F92-8B01-8845C54A613EQ28475815-920024FA-2140-4ABE-83FA-1FB97E3486F2Q28647054-F2DB1EA7-6853-475B-A761-39BD2D5F5BA6Q28749280-241CB5C3-2AAC-4131-8E78-02845A914539Q30164226-31932F3C-CD70-454F-8A0D-EDE22AC0A728Q30442041-773EAE85-A643-4EDD-82A5-2CEE644CF2B6Q30450251-15145C23-D889-4D82-A414-CA711D936265Q30833796-F339D7AE-99CC-4A4A-9EB6-F9193DD4D58FQ33267878-817EFBF6-C4BC-496B-9C82-99BC79477346Q33504867-C512BA0E-40F8-49E2-8D7B-BE8839CFF78CQ33570184-50761807-E248-420E-B57A-2C6E8D53967CQ33578860-B6D028CE-30D4-45DF-8EE5-3D1BECBEE23DQ33584270-41556CA1-1966-41AE-8E8C-83217CA42F3BQ33634208-A356384B-304F-4A82-A5EE-E60411586623Q33635406-A595A244-4098-4B5B-9FCD-C810F6286B08Q33690185-3CA29FE6-DD27-4127-9D1C-736E06E2D32AQ33758094-6D8FC9A9-CE62-4159-A78A-D91A1B419834Q33794163-7C829CC1-C880-46BB-86EE-F39C8A96496D
P2860
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
1985年论文
@zh
1985年论文
@zh-cn
name
Plasminogen activators, tissue degradation, and cancer.
@en
Plasminogen activators, tissue degradation, and cancer.
@nl
type
label
Plasminogen activators, tissue degradation, and cancer.
@en
Plasminogen activators, tissue degradation, and cancer.
@nl
prefLabel
Plasminogen activators, tissue degradation, and cancer.
@en
Plasminogen activators, tissue degradation, and cancer.
@nl
P2093
P1476
Plasminogen activators, tissue degradation, and cancer.
@en
P2093
Andreasen PA
Grøndahl-Hansen J
Kristensen P
Nielsen LS
P304
P577
1985-01-01T00:00:00Z